구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | autologous stem cell transplantation (autologous stem cell transplantation) Legend Biotech USA Inc·Multiple Myeloma, Newly Diagnosed 93 trials |
|---|---|
Overview Program | autologous stem cell transplantation |
Overview Company | Legend Biotech USA Inc |
Overview Modality | ANTIBODY |
Overview Target | Multiple Myeloma, Newly Diagnosed |
Overview Indication | Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | targeting, multireceptor |
MoA Biomarker | biomarker and therapeutic target |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | Efficacy of anti-GD2 antibody immunotherapy with filgrastim and teceleukin versus standard treatment with sargramostim, aldesleukin and isotretinoin in children with high-risk neuroblastoma.. Granulocyte-macrophage colony-stimulating factor (GM-CSF), aldesleukin and isotretinoin are unavailable in Japan, necessitating alternative cytokines for dinutuximab immunotherapy. We compared the efficacy of… |
Toxicology CRS | Reported |
Clinical Safety signal | Efficacy of anti-GD2 antibody immunotherapy with filgrastim and teceleukin versus standard treatment with sargramostim, aldesleukin and isotretinoin in children with high-risk neuroblastoma.. Granulocyte-macrophage colony-stimulating factor (GM-CSF), aldesleukin and isotretinoin are unavailable in Japan, necessitating alternative cytokines for dinutuximab immunotherapy. We compared the efficacy of… |
Clinical Selected reported efficacy | ORR 73.33% |
Clinical Reported ORR | 73.33% |
Clinical Reported PFS | 71.8 |
Clinical Reported OS | 100 |
Clinical Result source | ClinicalTrials.gov NCT02722941 |
Clinical Program phase | PHASE_2 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT02722941 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | autologous stem cell transplantation (autologous stem cell transplantation) Legend Biotech USA Inc·Multiple Myeloma, Newly Diagnosed 93 trials |
|---|---|
Overview Program | autologous stem cell transplantation |
Overview Company | Legend Biotech USA Inc |
Overview Modality | ANTIBODY |
Overview Target | Multiple Myeloma, Newly Diagnosed |
Overview Indication | Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | targeting, multireceptor |
MoA Biomarker | biomarker and therapeutic target |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | PD |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | Efficacy of anti-GD2 antibody immunotherapy with filgrastim and teceleukin versus standard treatment with sargramostim, aldesleukin and isotretinoin in children with high-risk neuroblastoma.. Granulocyte-macrophage colony-stimulating factor (GM-CSF), aldesleukin and isotretinoin are unavailable in Japan, necessitating alternative cytokines for dinutuximab immunotherapy. We compared the efficacy of… |
Toxicology CRS | Reported |
Clinical Safety signal | Efficacy of anti-GD2 antibody immunotherapy with filgrastim and teceleukin versus standard treatment with sargramostim, aldesleukin and isotretinoin in children with high-risk neuroblastoma.. Granulocyte-macrophage colony-stimulating factor (GM-CSF), aldesleukin and isotretinoin are unavailable in Japan, necessitating alternative cytokines for dinutuximab immunotherapy. We compared the efficacy of… |
Clinical Selected reported efficacy | ORR 73.33% |
Clinical Reported ORR | 73.33% |
Clinical Reported PFS | 71.8 |
Clinical Reported OS | 100 |
Clinical Result source | ClinicalTrials.gov NCT02722941 |
Clinical Program phase | PHASE_2 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT02722941 |
추천 비교
추천 비교